Systemic bioavailability of hydrofluoroalkane (HFA) formulations of fluticasone/salmeterol in healthy volunteers via pMDI alone and spacer
- 10 May 2010
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 69 (6) , 637-644
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Seretide (GlaxoSmithKline, UK) is a combination inhaler which contains both fluticasone (FP) and salmeterol (SM).• A generic fluticasone/salmeterol (FP/SM) combination inhaler (Neolab, UK) has recently been developed.• Determination of therapeutic equivalence is essential in the development of generic products. WHAT THIS STUDY ADDS • This paper determines that in vitro fine particle dose may not predict pharmacokinetic and systemic pharmacodynamic outcomes.• This paper shows that the generic and reference products were equivalent in terms of FP, but not SM pharmacokinetics.• No significant differences were found between generic and reference products in terms of either adrenal suppression or hypokalaemia.AIM To compare a test version of HFA fluticasone/salmeterol (FP/SM) combination inhaler (Neolab, UK) with the reference product Seretide (GlaxoSmithKline, UK).METHODS An in vitro Anderson cascade impactor was used to compare the fine particle dose (vs. reference (T vs. R) formulations of FP/SM 250/25 µg pMDI in healthy volunteers. In study 1 blood pharmacokinetic analysis using oral charcoal block was performed over 24 h following a single dose of four puffs via pMDI alone. In study 2 systemic bioactivity was measured following single doses of four and eight puffs via a spacer device: serum potassium (K+) to reflect SM, and overnight urinary cortisol : creatinine (OUCC) for FP. An early pharmacokinetic profile was also assessed over 120 min.RESULTS The in vitro fine particle dose was similar for test vs. reference pMDI alone and via spacer. The results of both studies were consistent: No significant differences between formulations were seen in terms of FP kinetics. Analysis of SM kinetics revealed superiority of the test product. No significant dose–response or difference in T : R ratio was noted for OUCC. Fall in K+ revealed a significant dose–response with a non‐significant T : R ratio.CONCLUSIONS The in vitro fine particle dose may not predict pharmacokinetic and systemic pharmacodynamic outcomes. Single dosing studies with fluticasone/salmeterol 250/25 µg via pMDI or with spacer showed pharmacokinetic equivalence with FP, but not SM. No significant difference between formulations was seen with either adrenal suppression or hypokalaemia.Keywords
This publication has 19 references indexed in Scilit:
- Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthmaThorax, 2005
- Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjectsRespiratory Medicine, 2005
- Can Guideline-defined Asthma Control Be Achieved?American Journal of Respiratory and Critical Care Medicine, 2004
- Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalersJournal of Allergy and Clinical Immunology, 2003
- Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice dailyJournal of Allergy and Clinical Immunology, 2003
- Adrenal suppression with inhaled corticosteroidsAnnals of Allergy, Asthma & Immunology, 2001
- Pharmacokinetics and systemic β2‐adrenoceptor‐mediated responses to inhaled salbutamolBritish Journal of Clinical Pharmacology, 2001
- Comparison of Addition of Salmeterol to Inhaled Steroids With Doubling of the Dose of Inhaled SteroidsAmerican Journal of Respiratory and Critical Care Medicine, 1996
- Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients.Thorax, 1995
- Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthmaThe American Journal of Medicine, 1994